[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
avidresearch posts on X about $abvx, delta, $38b, $3b the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence finance XXXX% stocks XXXX% cryptocurrencies XXXX%
Social topic influence $abvx 11.29%, delta 3.23%, $38b 1.61%, $3b 1.61%, $rare 1.61%, $wve 1.61%, rates 1.61%, $nktr 1.61%, $janx 1.61%, $alny XXXX%
Top accounts mentioned or mentioned by @amaymd @jfais20 @jacobplieth @mikeconvente @houndcl @nolastevedore @bioclouseau @jinghanghu @aaronrosenblum5 @jiantkwazi @pickingmyown @apexonco @sharkbiotech @pbmech @oncinvestor @dgtrading101 @bigpharmaguy @sagittacapital @sentivcapital @pikacapital
Top assets mentioned SuperRare (RARE) Janux Therapeutics, Inc. Common Stock (JANX) Alnylam Pharmaceuticals, Inc. (ALNY) BridgeBio Pharma, Inc. Common Stock (BBIO) Gilead Sciences, Inc. (GILD)
Top posts by engagements in the last XX hours
"Maybe $RARE gets aquired if OI hits. $2.5-$3B /year sales with current pipeline and Angelman readout gives further upside. All that while trading at $3.8B valuation" @avidresearch on X 2025-07-09 17:31:04 UTC 10.7K followers, 3348 engagements
"$WVE typically does earnings call in first week of Aug. July 30th is a bit early. We may see AATD updated multi-dose data with this ER" @avidresearch on X 2025-07-24 11:40:56 UTC 10.7K followers, 7308 engagements
"@JacobPlieth @ApexOnco Really sad to see how much time and energy was wasted on TIGIT" @avidresearch on X 2025-07-24 11:35:53 UTC 10.7K followers, XXX engagements
"$ABVX went through @A_May_MD summary and as usual found it to be very compelling. Is market able to appreciate delta for clinical remission is for Week X (vs 12) while comparing topline results. Well established that remission rates increase over time" @avidresearch on X 2025-07-22 12:44:14 UTC 10.7K followers, 3639 engagements
"I&I space is seeing a shift from targeting single/multiple cytokines to homeostasis. If long term safety validates lower serious infection risks with these approaches will lead to a big shift. $NKTR $ABVX" @avidresearch on X 2025-07-25 13:12:08 UTC 10.7K followers, 6522 engagements
"@JoseRestonVA @jfais20 $JANX R&D day slides" @avidresearch on X 2025-07-25 02:27:53 UTC 10.7K followers, 5938 engagements
"This reminds me a bit of $BBIO month XX time point for overall survival while $ALNY used up to XX months" @avidresearch on X 2025-07-22 12:45:30 UTC 10.7K followers, 1013 engagements
"@plainyogurt21 @JinghangHu @jfais20 @AaronRosenblum5 @houndcl INHBE pace of fat loss will be slower than GLP1s so unlikely to be an issue" @avidresearch on X 2025-07-23 11:13:15 UTC 10.7K followers, XXX engagements
"Endoscopic improvement delta almost Rinvoq like but with cleaner safety. Cc @A_May_MD" @avidresearch on X 2025-07-22 20:12:25 UTC 10.7K followers, 3317 engagements
"@PikaCapital $gmab 2029 darzalex patent cliff" @avidresearch on X 2025-07-16 12:51:17 UTC 10.7K followers, XXX engagements
"Guys $abvx showed these impressive results at week X as @A_May_MD repeatedly pointed out vs recent ph2 trials that were using wk12 (or longer). Makes results that much more impressive" @avidresearch on X 2025-07-22 20:46:28 UTC 10.7K followers, 5788 engagements
"I know in AML mono activity of $CRIS $FTSV. Did someone also compare if mono $CRIS IRAK4 activity in DLBCL also mono $FTSV CD47 data in DLBCL If so that is one heck of a data point" @avidresearch on X 2021-03-10 23:29:56 UTC 10.7K followers, XX engagements